FDA Inspection 1074746 — ACS Dobfar s.p.a.
The FDA completed an inspection of ACS Dobfar s.p.a. on November 8, 2018 in Agrate Brianza. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 8, 2018
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Agrate Brianza (Italy)
Additional Details
Postmarket Adverse Drug Experience (PADE)